The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma.
 
Tongyu Lin
No Relationships to Disclose
 
Bin Liu
No Relationships to Disclose
 
Xingxiang Pu
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Xiaobo Du
No Relationships to Disclose
 
Ning Mo
No Relationships to Disclose
 
Zhengbo Song
No Relationships to Disclose
 
Liwei Zhou
Employment - QiLu Pharmaceutical
Research Funding - QiLu Pharmaceutical
 
Xianlin Duan
Employment - QiLu Pharmaceutical
Research Funding - QiLu Pharmaceutical
 
Yanan Zhu
Employment - QiLu Pharmaceutical
Research Funding - QiLu Pharmaceutical
 
Xiaoyan Kang
Employment - QiLu Pharmaceutical
Research Funding - QiLu Pharmaceutical